TY  - JOUR
AU  - Karimian-Jazi, Kianush
AU  - Wildemann, Brigitte
AU  - Diem, Ricarda
AU  - Schwarz, Daniel
AU  - Hielscher, Thomas
AU  - Wick, Wolfgang
AU  - Bendszus, Martin
AU  - Breckwoldt, Michael
TI  - Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.
JO  - Neurology
VL  - 5
IS  - 5
SN  - 2332-7812
CY  - Philadelphia, Pa.
PB  - Lippincott Williams & Wilkins
M1  - DKFZ-2018-01904
SP  - e480
PY  - 2018
N1  - Neurology Neuroimmunology & Neuroinflammation
AB  - To assess the diagnostic value of gadolinium (Gd) contrast administration in MRI follow-up examinations of patients with MS if the T2 lesion load is stable.We included 100 patients with MS with at least 2 cranial MRI follow-up examinations (mean follow-up time 4.0 ± 2.6 years). MRI was performed at 3 Tesla with a standardized protocol including T2-weighted, fluid-attenuated inversion recovery (FLAIR) and T1-weighted contrast-enhanced sequences. Images were analyzed for T2/FLAIR and contrast-enhancing (CE) lesions by 3 independent neuroradiologists. Isolated Gd-enhancing lesions without correlate in T2 and FLAIR images, and reactivated Gd+ lesions were further assessed for size and signal intensity.We identified a total of 343 new T2 lesions and 152 CE lesions in a total of 559 MRI follow-up examinations. New T2/FLAIR lesions were present in 30
LB  - PUB:(DE-HGF)16
C6  - pmid:30038948
C2  - pmc:PMC6053940
DO  - DOI:10.1212/NXI.0000000000000480
UR  - https://inrepo02.dkfz.de/record/141398
ER  -